Weekly Research Analysts’ Ratings Changes for Corteva (CTVA)

Corteva (NYSE: CTVA) recently received a number of ratings updates from brokerages and research firms:

• 5/13/2026 – Corteva had its price target raised by CICC Research from $80.00 to $93.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Corteva had its price target raised by Deutsche Bank Aktiengesellschaft from $90.00 to $100.00.
• 5/7/2026 – Corteva was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 5/7/2026 – Corteva had its price target raised by Royal Bank Of Canada from $95.00 to $97.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Corteva had its price target raised by UBS Group AG from $88.00 to $90.00. They now have a “neutral” rating on the stock.
• 5/7/2026 – Corteva had its price target raised by Citigroup Inc. from $83.00 to $85.00. They now have a “neutral” rating on the stock.
• 5/7/2026 – Corteva had its price target raised by Jefferies Financial Group Inc. from $95.00 to $97.00.
• 5/6/2026 – Corteva had its price target raised by BNP Paribas Exane from $74.00 to $77.00.
• 4/29/2026 – Corteva had its price target raised by Rothschild & Co Redburn from $80.00 to $90.00. They now have a “neutral” rating on the stock.
• 4/24/2026 – Corteva had its price target raised by Royal Bank Of Canada from $89.00 to $95.00. They now have an “outperform” rating on the stock.
• 4/22/2026 – Corteva had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 4/22/2026 – Corteva had its price target raised by Oppenheimer Holdings, Inc. from $86.00 to $89.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Corteva had its price target raised by Wells Fargo & Company from $85.00 to $90.00. They now have an “overweight” rating on the stock.
• 4/15/2026 – Corteva had its price target raised by Mizuho from $82.00 to $94.00. They now have an “outperform” rating on the stock.
• 4/14/2026 – Corteva had its price target raised by The Goldman Sachs Group, Inc. from $88.00 to $96.00. They now have a “buy” rating on the stock.
• 4/9/2026 – Corteva had its price target raised by UBS Group AG from $80.00 to $88.00. They now have a “neutral” rating on the stock.
• 3/31/2026 – Corteva had its price target raised by Argus from $80.00 to $91.00. They now have a “buy” rating on the stock.
• 3/26/2026 – Corteva had its price target raised by Berenberg Bank from $68.00 to $78.00. They now have a “hold” rating on the stock.

Corteva Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Monday, June 1st will be paid a $0.18 dividend. The ex-dividend date is Monday, June 1st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. Corteva’s payout ratio is presently 42.35%.

Insider Activity at Corteva

In other news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the transaction, the insider directly owned 8,090 shares in the company, valued at approximately $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.15% of the company’s stock.

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.